Status:
RECRUITING
Clonal Architecture of ASXL1-mutated Myelofibrosis
Lead Sponsor:
University Hospital, Angers
Conditions:
Myelofibrosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
Detailed Description
The clonal architecture of myelofibrosis patients is still little described. Inconsistent results in terms of the prognostic value of some mutations are observed in the literature, in particular conce...
Eligibility Criteria
Inclusion Criteria:
- Adults (age ≥18 years),
- Affiliated to the national social security system,
- ASXL1 mutated primary or secondary myelofibrosis,
- Signed the consent to participate in the study,
- Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).
Exclusion Criteria:
- Patient with another active hematological disease or cancer at the time of diagnosis,
- Person subject to legal protection scheme or incapable of giving consent.
Key Trial Info
Start Date :
April 24 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 23 2031
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05710211
Start Date
April 24 2023
End Date
April 23 2031
Last Update
March 9 2026
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers
Angers, France
2
CHRU Brest
Brest, France
3
CH Cholet
Cholet, France
4
CHU Henri MONDOR
Créteil, France, 94010